251 related articles for article (PubMed ID: 16038646)
1. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
Lyman GH
J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
[TBL] [Abstract][Full Text] [Related]
2. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
3. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
4. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
5. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
8. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
Daniel DB; Crawford J;
Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
[TBL] [Abstract][Full Text] [Related]
9. First-Cycle CSF use in breast cancer and NHL: guidelines and recommendations.
Al-Kali A; Ozer H
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):7-12. PubMed ID: 17370923
[TBL] [Abstract][Full Text] [Related]
10. Myeloid growth factors clinical practice guidelines in oncology.
Crawford J; Althaus B; Armitage J; Blayney DW; Cataland S; Dale DC; Demetri GD; Foran J; Heaney ML; Htoy S; Kloth DD; Lyman GH; Michaud L; Motl S; Vadhan-Raj S; Wong MK;
J Natl Compr Canc Netw; 2005 Jul; 3(4):540-55. PubMed ID: 16038645
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
12. Balancing the benefits and costs of colony-stimulating factors: a current perspective.
Lyman GH
Semin Oncol; 2003 Aug; 30(4 Suppl 13):10-7. PubMed ID: 14508715
[TBL] [Abstract][Full Text] [Related]
13. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
Barnes G; Pathak A; Schwartzberg L
Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
16. A predictive model for neutropenia associated with cancer chemotherapy.
Lyman GH
Pharmacotherapy; 2000 Jul; 20(7 Pt 2):104S-111S. PubMed ID: 10905685
[TBL] [Abstract][Full Text] [Related]
17. [G-CSF in oncology].
Viret F; Gonçalves A; Tarpin C; Chabannon C; Viens P
Bull Cancer; 2006 May; 93(5):463-71. PubMed ID: 16777624
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
Crawford J
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based use of colony-stimulating factors in elderly cancer patients.
Lyman GH; Kuderer N; Agboola O; Balducci L
Cancer Control; 2003; 10(6):487-99. PubMed ID: 14652525
[TBL] [Abstract][Full Text] [Related]
20. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.
Cosler LE; Calhoun EA; Agboola O; Lyman GH
Pharmacotherapy; 2004 Apr; 24(4):488-94. PubMed ID: 15098803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
